Imaging Procedure and Clinical Studies of 18 FFP‑CIT PET
10.1007/s13139-024-00840-x
- Author:
Changhwan SUNG
1
;
Seung Jun OH
;
Jae Seung KIM
Author Information
1. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic‑Ro 43‑Gil, Songpa‑Gu, Seoul 05505, Republic of Korea
- Publication Type:REVIEW
- From:Nuclear Medicine and Molecular Imaging
2024;58(4):185-202
- CountryRepublic of Korea
- Language:English
-
Abstract:
N-3-[18F]fluoropropyl-2β-carbomethoxy-3β-4-iodophenyl nortropane ([18F]FP-CIT) is a radiopharmaceutical for dopamine transporter (DAT) imaging using positron emission tomography (PET) to detect dopaminergic neuronal degeneration in patients with parkinsonian syndrome. [18F]FP-CIT was granted approval by the Ministry of Food and Drug Safety in 2008 as the inaugural radiopharmaceutical for PET imaging, and it has found extensive utilization across numerous institutions in Korea. This review article presents an imaging procedure for [1818 F]FP-CIT PET to aid nuclear medicine physicians in clinical practice and systematically reviews the clinical studies associated with [18 F]FP-CIT PET.
